CA3067539A1 - Interferon prodrug for the treatment of cancer - Google Patents
Interferon prodrug for the treatment of cancer Download PDFInfo
- Publication number
- CA3067539A1 CA3067539A1 CA3067539A CA3067539A CA3067539A1 CA 3067539 A1 CA3067539 A1 CA 3067539A1 CA 3067539 A CA3067539 A CA 3067539A CA 3067539 A CA3067539 A CA 3067539A CA 3067539 A1 CA3067539 A1 CA 3067539A1
- Authority
- CA
- Canada
- Prior art keywords
- ifn
- cancer
- interferon
- nucleic acid
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762522564P | 2017-06-20 | 2017-06-20 | |
| US62/522,564 | 2017-06-20 | ||
| PCT/US2018/037982 WO2018236701A1 (en) | 2017-06-20 | 2018-06-18 | INTERFERON PRODRUCE FOR THE TREATMENT OF CANCER |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3067539A1 true CA3067539A1 (en) | 2018-12-27 |
Family
ID=64737368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3067539A Pending CA3067539A1 (en) | 2017-06-20 | 2018-06-18 | Interferon prodrug for the treatment of cancer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200123227A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3641829A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2020528878A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20200015742A (cg-RX-API-DMAC10.html) |
| CN (1) | CN111050803A (cg-RX-API-DMAC10.html) |
| CA (1) | CA3067539A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018236701A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210130430A1 (en) | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| MX2020012251A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina-2 activables y metodos de uso de los mismos. |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| CA3136602A1 (en) | 2019-04-15 | 2020-10-22 | Qwixel Therapeutics Llc | Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer |
| BR112021022666A2 (pt) | 2019-05-14 | 2022-03-29 | Werewolf Therapeutics Inc | Frações de separação e seus métodos e uso |
| CN114341189A (zh) | 2019-06-12 | 2022-04-12 | 奥美药业有限公司 | 全新il-15前药及其应用 |
| AU2020316002B2 (en) * | 2019-07-25 | 2026-05-07 | The University Of Chicago | Compositions and methods comprising protease-activated therapeutic agents |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| AU2021205981A1 (en) | 2020-01-11 | 2022-07-14 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| US20240076355A1 (en) * | 2021-01-14 | 2024-03-07 | AskGene Pharma, Inc. | Interferon Prodrugs and Methods of Making and Using the Same |
| KR20230157448A (ko) * | 2021-03-16 | 2023-11-16 | 싸이톰스 테라퓨틱스, 인크. | 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법 |
| KR20240021943A (ko) * | 2021-06-18 | 2024-02-19 | 남미 테라퓨틱스, 인크. | 암의 치료에 사용하기 위한 마스킹된 유형 I 인터페론 (IFNα 및 IFNβ)을 포함하는 융합 단백질 조성물(들) 및 그의 방법 |
| EP4387987A2 (en) * | 2021-08-18 | 2024-06-26 | Werewolf Therapeutics, Inc. | Activatable inteferon polypeptides and methods of use thereof |
| US20240400633A1 (en) * | 2021-09-30 | 2024-12-05 | Orionis Biosciences, Inc. | Split human ifn-gamma and tnf-alpha constructs and uses thereof |
| WO2023060156A2 (en) * | 2021-10-08 | 2023-04-13 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| MX2024004301A (es) * | 2021-10-08 | 2024-04-26 | Cytomx Therapeutics Inc | Construcciones de citocinas activables y metodos combinados. |
| US20240067691A1 (en) * | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| WO2024186193A1 (ko) * | 2023-03-08 | 2024-09-12 | 인제대학교 산학협력단 | 국소적 방사선 치료에서 전신성 항암 치료를 위한 조성물 |
| KR20260026098A (ko) * | 2023-05-12 | 2026-02-25 | 리제너론 파아마슈티컬스, 인크. | 인터페론 수용체 길항제 및 이의 용도 |
| EP4750813A1 (en) * | 2023-07-25 | 2026-06-03 | TJ Biopharma (Shanghai) Co., Ltd. | Masked interferon fusion proteins and uses thereof |
| WO2025201363A1 (zh) * | 2024-03-27 | 2025-10-02 | 高雄医学大学 | 细胞因子阻断抗体及其应用 |
| WO2026158523A1 (en) * | 2025-01-24 | 2026-07-30 | Tj Biopharma (Hangzhou) Co., Ltd. | Masked multifunctional proteins |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL197568B1 (pl) * | 1997-12-19 | 2008-04-30 | Applied Research Systems | Kompleks zawierający IFN typu I oraz podjednostkę IFNAR, jego zastosowanie, cząsteczka DNA i wektor ją zawierający, komórka gospodarza transformowana wektorem, kompozycja farmaceutyczna, lek, zastosowanie IFNAR, zastosowanie IFN typu I i podjednostki IFNAR, sposób wytwarzania białka fuzyjnego oraz sposób przedłużania okresu trwałości IFN |
| US20040014652A1 (en) * | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
| EP2190861A4 (en) * | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| US20100189727A1 (en) * | 2008-12-08 | 2010-07-29 | Tegopharm Corporation | Masking Ligands For Reversible Inhibition Of Multivalent Compounds |
| US8399219B2 (en) * | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
| US11291721B2 (en) * | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
-
2018
- 2018-06-18 JP JP2019570445A patent/JP2020528878A/ja active Pending
- 2018-06-18 EP EP18820121.4A patent/EP3641829A4/en not_active Withdrawn
- 2018-06-18 CN CN201880053451.8A patent/CN111050803A/zh active Pending
- 2018-06-18 WO PCT/US2018/037982 patent/WO2018236701A1/en not_active Ceased
- 2018-06-18 CA CA3067539A patent/CA3067539A1/en active Pending
- 2018-06-18 US US16/624,648 patent/US20200123227A1/en not_active Abandoned
- 2018-06-18 KR KR1020207000744A patent/KR20200015742A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020101640A (ru) | 2021-07-20 |
| RU2020101640A3 (cg-RX-API-DMAC10.html) | 2021-09-23 |
| EP3641829A1 (en) | 2020-04-29 |
| JP2020528878A (ja) | 2020-10-01 |
| US20200123227A1 (en) | 2020-04-23 |
| EP3641829A4 (en) | 2021-04-21 |
| KR20200015742A (ko) | 2020-02-12 |
| WO2018236701A1 (en) | 2018-12-27 |
| CN111050803A (zh) | 2020-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200123227A1 (en) | Interferon prodrug for the treatment of cancer | |
| AU2018342246B2 (en) | T cell receptors recognizing mutated p53 | |
| US10479997B2 (en) | Compositions and methods for diagnosis and treatment of prostate cancer | |
| CA2964363A1 (en) | Compositions and methods for identification, assessment, prevention, and treatment of t-cell exhaustion using cd39 biomarkers and modulators | |
| JP2026074003A (ja) | B7h3標的タンパク質及びその使用方法 | |
| CA2952181A1 (en) | Activating jak kinase biomarkers predictive of anti-immune checkpoint inhibitor response | |
| CA2830787C (en) | Dominant negative hsp110 mutant and its use in prognosing and treating cancers | |
| JP2017501137A (ja) | Wnt経路インヒビターに関連する予測バイオマーカーの同定 | |
| KR20210102331A (ko) | 암 및 기타 질환의 진단 및 치료를 위한 종양 촉진 암종 관련 섬유아세포의 식별 및 표적화 | |
| US20200353080A1 (en) | Cancer methods | |
| WO2018215614A1 (en) | Fusion protein for enhancing intestinal regeneration | |
| WO2006014999A2 (en) | Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease | |
| US20200261550A1 (en) | Compositions and methods for treating cancer using rhoa dominant negative forms | |
| US20210253664A1 (en) | Tlr9 ligand trap | |
| JP7599716B2 (ja) | がんおよび他の疾患の診断および処置のための病原性細胞外マトリックスの同定および標的化 | |
| RU2788736C2 (ru) | Пролекарство интерферона для лечения рака | |
| US8404810B2 (en) | Compositions and methods of use for modulators of polypeptides and polynucleotides in treating breast cancer and melanoma | |
| US20180052169A1 (en) | Tsp1 as a marker for cancer | |
| CN110713544A (zh) | 融合基因plekha6-ntrk3及其在lch中的应用 | |
| JPWO2003031620A1 (ja) | 新規クラスiiサイトカイン受容体 | |
| WO2005070448A2 (en) | Methods of use for secreted frizzled-related protein 3 (sfrp-3) in the prevention and treatment of disease | |
| JP6233932B2 (ja) | BBF2H7(BBF2 human homologue on chromosome7)部分アミノ酸配列を有するペプチドまたはそれに結合する抗体を含む細胞増殖調節用組成物 | |
| US20100028867A1 (en) | LRRTM1 Compositions and Methods of Their Use for the Diagnosis and Treatment of Cancer | |
| JP2022515131A (ja) | リン酸化ダイサー抗体およびその使用方法 | |
| US20070274988A1 (en) | Kiaa0779, Splice Variants Thereof, and Methods of Their Use |